Navamedic Dividend

Dividend criteria checks 0/6

Navamedic does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	kr0.22
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NAVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NAVA's dividend payments have been increasing.

Dividend Yield vs Market

Navamedic Dividend Yield vs Market

How does NAVA dividend yield compare to the market?
Segment	Dividend Yield
Company (NAVA)	n/a
Market Bottom 25% (NO)	3.3%
Market Top 25% (NO)	7.7%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (NAVA)	0%

Notable Dividend: Unable to evaluate NAVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NAVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NAVA's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NAVA has not reported any payouts.

Navamedic Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021

New 90-day low: kr17.45

New 90-day low: kr18.20

Chief Executive Officer exercised options to buy kr2.3m worth of stock.

New 90-day low: kr18.50

Earnings released

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies